Romosozumab Treatment Guidelines for Osteoporosis
Indications and Contraindications
- The American College of Physicians recommends romosozumab only in postmenopausal females with osteoporosis at very high risk for fracture, with a mean age >74 years in trials, and after consideration of cardiovascular contraindications 1, 2
- The American College of Rheumatology conditionally recommends against romosozumab in moderate-risk patients due to cardiovascular risks, reserving it only for those unable to tolerate other agents 3, 4
Treatment Duration and Sequential Therapy
- FDA labeling limits romosozumab to 12 monthly doses maximum because the anabolic effect wanes after 12 months, and mandatory sequential anti-resorptive therapy is required after completion to maintain BMD gains 4, 2
- The American College of Rheumatology recommends planning for sequential anti-resorptive therapy after romosozumab completion to maintain BMD gains 3, 4
Required Documentation for Approval
- Prior osteoporosis treatment history, including specific medications tried, duration of each treatment, and reason for discontinuation or failure, is necessary for approval 4, 3
- Documentation of total number of previous romosozumab doses is required to ensure less than 12 doses total 4
Romosozumab Treatment Guidelines
Indications and Contraindications
- The American College of Physicians recommends romosozumab for postmenopausal females with osteoporosis at very high risk for fracture, as indicated by multiple documented fragility fractures 5, 6, 7
Treatment Duration and Sequencing
- Romosozumab treatment should be limited to exactly 12 monthly doses, after which the anabolic effect wanes, and mandatory transition to anti-resorptive therapy is required to maintain bone mineral density gains 5, 6